A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments

被引:26
作者
Fischer, Krista [1 ]
Goetghebeur, Els [2 ]
Vrijens, Bernard [3 ]
White, Ian R. [1 ]
机构
[1] Univ Forvie Site, MRC Biostat Unit, Inst Publ Hlth, Cambridge CB2 0SR, England
[2] Univ Ghent, Dept Appl Math & Comp Sci, B-9000 Ghent, Belgium
[3] Pharm Syst SA, AARDEX Grp, BE-4600 Vise, Belgium
基金
英国医学研究理事会;
关键词
Causal inference; Randomized-controlled trials; Structural mean models; CLINICAL-TRIALS; EFFICACY;
D O I
10.1093/biostatistics/kxq053
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose a structural mean modeling approach to obtain compliance-adjusted estimates for treatment effects in a randomized-controlled trial comparing 2 active treatments. The model relates an individual's observed outcome to his or her counterfactual untreated outcome through the observed receipt of active treatments. Our proposed estimation procedure exploits baseline covariates that predict compliance levels on each arm. We give a closed-form estimator which allows for differential and unexplained selectivity (i.e. noncausal compliance-outcome association due to unobserved confounding) as well as a nonparametric error distribution. In a simple linear model for a 2-arm trial, we show that the distinct causal parameters are identified unless covariate-specific expected compliance levels are proportional on both treatment arms. In the latter case, only a linear contrast between the 2 treatment effects is estimable and may well be of key interest. We demonstrate the method in a clinical trial comparing 2 antidepressants.
引用
收藏
页码:247 / 257
页数:11
相关论文
共 25 条
[1]  
[Anonymous], 1999, INT C HARM TECHN REQ, P1
[2]  
Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO
[3]  
2-V
[4]   Development of an antidepressant compliance questionnaire [J].
Demyttenaere, K ;
Bruffaerts, R ;
Albert, A ;
Mesters, P ;
Dewé, W ;
Debruyckere, K ;
Sangeleer, M .
ACTA PSYCHIATRICA SCANDINAVICA, 2004, 110 (03) :201-207
[5]   Six-month compliance with antidepressant medication in the treatment of major depressive disorder [J].
Demyttenaere, Koen ;
Adelin, Albert ;
Patrick, Mesters ;
Walthere, Dewe ;
Katrien, De Bruyckere ;
Michele, Sangeleer .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (01) :36-42
[6]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[7]   Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up [J].
Dunn, G ;
Maracy, M ;
Dowrick, C ;
Ayuso-Mateos, JL ;
Dalgard, OS ;
Page, H ;
Lehtinen, V ;
Casey, P ;
Wilkinson, C ;
Vázquez-Barquero, JL ;
Wilkinson, G .
BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 :323-331
[8]  
EFRON B, 1991, J AM STAT ASSOC, V86, P9, DOI 10.2307/2289707
[9]   Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases [J].
Ellenberg, SS ;
Temple, R .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :464-470
[10]  
Goetghebeur E., 1997, J R STAT SOC C-APPL, V46, P351